Use of multiple biological markers in radiotherapy-treated head and neck cancer.
Authors
Silva, PriyamalSlevin, Nicholas J
Sloan, Philip
Valentine, Helen R
Ryder, W David J
Price, Patricia M
West, Catharine M L
Homer, Jarrod J
Affiliation
School of Cancer & Enabling Sciences, The University of Manchester, Manchester, UK.Issue Date
2010-06
Metadata
Show full item recordAbstract
OBJECTIVE: Management of patients with head and neck squamous cell carcinoma is often based on clinical parameters, with little appreciation of the underlying tumour biology. Single biological marker studies fail to acknowledge the complexity of these tumours. Our aim was to define a profile of biological markers associated with outcome. DESIGN: This retrospective study involved consecutive patients with oropharyngeal squamous cell carcinoma treated with primary radiotherapy between 1996 and 2001. Pre-treatment biopsies were used to study the immunohistochemical expression of nine biological markers. Markers were chosen to reflect biologically relevant pathways. RESULTS: Following analysis of nine markers, a profile of two markers was derived (carbonic anhydrase 9 and major vault protein), the co-expression of which conferred a significantly poor probability of locoregional control. The prognostic effect of these biomarkers in combination was greater than their effect individually. CONCLUSION: Biomarker profiles can be established which highlight large differences in locoregional control. Identifying tumours that express both carbonic anhydrase 9 and major vault protein may facilitate patient selection for more aggressive treatment.Citation
Use of multiple biological markers in radiotherapy-treated head and neck cancer. 2010, 124 (6):650-8 J Laryngol OtolJournal
The Journal of Laryngology and OtologyDOI
10.1017/S0022215110000228PubMed ID
20388242Type
ArticleLanguage
enISSN
1748-5460ae974a485f413a2113503eed53cd6c53
10.1017/S0022215110000228
Scopus Count
Related articles
- The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
- Authors: Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, Oosterwijk E, van der Kogel AJ, Kaanders JH
- Issue date: 2006 Jun
- The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
- Authors: De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S
- Issue date: 2005 Apr 25
- Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
- Authors: Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL
- Issue date: 2006 Feb 10
- Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
- Authors: Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hänsgen G, Dunst J, Vordermark D
- Issue date: 2006 Dec 1
- Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
- Authors: Schrijvers ML, van der Laan BF, de Bock GH, Pattje WJ, Mastik MF, Menkema L, Langendijk JA, Kluin PM, Schuuring E, van der Wal JE
- Issue date: 2008 Sep 1